“Global Magnetic Resonance Imaging (MRI) systems market set to grow to $9.9bn by 2024” says new Visiongain report

08 January 2019
Pharma

Visiongain has launched a new pharma report Global Magnetic Resonance Imaging (MRI) Systems Market Forecast 2019-2029: High-Field MRI, Ultra-High Field MRI, Low-Field MRI.

Rapid expansions in the applications of MRI and an increased medical awareness of MRI systems as a diagnostic tool have triggered strong growth in this market in recent years. As this trend continues, and new applications are discovered (coupled with continued product innovation), the market will continue to achieve strong revenue growth. The future of the MRI devices market look promising, as more innovative devices are in the R&D pipeline and eventually enters the market. In the recent years, there have been progressive improvements in the safety, comfort, convince and efficacy of MRI devices, yet there is potential for more innovation. With steady progression of the industry, MRI equipment will gain popularity among healthcare providers, with that market expanding worldwide and the devices developed to address a wider range of medical conditions. As MRI markets in developed countries mature, emerging national markets will continue to drive the growth of MRI sales, as a result of increased healthcare spending.

The lead analyst of the report commented "Opportunities in the market include the development and increased preference towards ultra-high field systems which are capable of imaging ions and neurotransmitters, ultimately achieving a new level of diagnostic imaging.

There are strong opportunities for market growth in rising countries such as China and India where the density of MRI scanners per million of the population is a major concern. As the global awareness of the benefits of MRI increases, and in response to strong patient demand, government spending in healthcare in these respective countries is expected to increase. This will ultimately provide strong opportunities for market players to direct their focus towards emerging countries, rather than in developed countries, where the MRI market is steadily reaching saturation."

Leading companies featured in the report include Aurora Healthcare US Corp, Bruker Corporation, Canon Medical Systems, Esaote SpA, GE Healthcare, Hitachi, Ltd., Neusoft Medical Systems Co., Ltd., Philips Healthcare, Shenzhen Anke High-tech Co., Ltd., Siemens Healthineers

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Bioreactors market set to grow to $1.6bn by 2024” says new Visiongain report

The bioreactors market is expected to grow over the forecast period owing to the increase in adoption of single use technologies and the growing popularity among pharmaceutical companies regarding the potential benefits of single-use bioreactors.

25 March 2019

Read

“Global Biosimilars and Follow-On Biologics Drugs market set to grow to $14bn by 2024” says new Visiongain report

Growth will be restrained in the biosimilar growth hormones submarket by steady uptake for branded therapies, high brand loyalty, as well as the launch of long-acting growth hormones.

21 March 2019

Read

“Global Asthma & COPD Therapies market set to grow to $46bn by 2024” says new Visiongain report

ecent studies and expert opinion suggest that the asthma and COPD market is more segregated than previously believed.

19 March 2019

Read

“Global Anaesthesia Drugs market set to grow to $11.8bn by 2024” says new Visiongain report

The intravenous route is the most commonly used route of administration owing to its high effectiveness during critical surgeries, its high adoption in hospitals, and availability of advanced intravenous drugs which cater the need of surgeons.

19 March 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever
WOOCS 2.2.1